The clinical and cost effectiveness of topotecan for ovarian cancer

C. Forbes, Elizabeth A Shirran, R. A. Lewis, A. M. Bagnall, S. Duffy, J. Kleijnen, G. ter Riet

    Research output: Contribution to journalArticle

    Original languageEnglish
    JournalHealth Technology Assessment
    Volume5
    Issue number28
    Publication statusPublished - 2001

    Cite this

    Forbes, C., Shirran, E. A., Lewis, R. A., Bagnall, A. M., Duffy, S., Kleijnen, J., & ter Riet, G. (2001). The clinical and cost effectiveness of topotecan for ovarian cancer. Health Technology Assessment, 5(28).

    The clinical and cost effectiveness of topotecan for ovarian cancer. / Forbes, C.; Shirran, Elizabeth A; Lewis, R. A.; Bagnall, A. M.; Duffy, S.; Kleijnen, J.; ter Riet, G.

    In: Health Technology Assessment, Vol. 5, No. 28, 2001.

    Research output: Contribution to journalArticle

    Forbes, C, Shirran, EA, Lewis, RA, Bagnall, AM, Duffy, S, Kleijnen, J & ter Riet, G 2001, 'The clinical and cost effectiveness of topotecan for ovarian cancer', Health Technology Assessment, vol. 5, no. 28.
    Forbes C, Shirran EA, Lewis RA, Bagnall AM, Duffy S, Kleijnen J et al. The clinical and cost effectiveness of topotecan for ovarian cancer. Health Technology Assessment. 2001;5(28).
    Forbes, C. ; Shirran, Elizabeth A ; Lewis, R. A. ; Bagnall, A. M. ; Duffy, S. ; Kleijnen, J. ; ter Riet, G. / The clinical and cost effectiveness of topotecan for ovarian cancer. In: Health Technology Assessment. 2001 ; Vol. 5, No. 28.
    @article{82d905fa7dee4d7f9ecefeefde3b7997,
    title = "The clinical and cost effectiveness of topotecan for ovarian cancer",
    author = "C. Forbes and Shirran, {Elizabeth A} and Lewis, {R. A.} and Bagnall, {A. M.} and S. Duffy and J. Kleijnen and {ter Riet}, G.",
    year = "2001",
    language = "English",
    volume = "5",
    journal = "Health Technology Assessment",
    issn = "1366-5278",
    publisher = "National Co-ordinating Centre for HTA",
    number = "28",

    }

    TY - JOUR

    T1 - The clinical and cost effectiveness of topotecan for ovarian cancer

    AU - Forbes, C.

    AU - Shirran, Elizabeth A

    AU - Lewis, R. A.

    AU - Bagnall, A. M.

    AU - Duffy, S.

    AU - Kleijnen, J.

    AU - ter Riet, G.

    PY - 2001

    Y1 - 2001

    M3 - Article

    VL - 5

    JO - Health Technology Assessment

    JF - Health Technology Assessment

    SN - 1366-5278

    IS - 28

    ER -